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Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Peroxiredoxins possess thioredoxin or glutathione peroxidase and
chaperone like activities and thereby protect cells from oxidative
insults. Recent studies, however, reveal additional functions of
peroxiredoxins in gene expression and inflammation related bio 
logical reactions such as tissue repair, parasite infection and
tumor progression. Notably, peroxiredoxin 1, the major mamma 
lian peroxiredoxin family protein, directly interacts with transcrip 
tion factors such as c Myc and NF κB in the nucleus. Additionally,
peroxiredoxin 1 is secreted from some cells following stimulation
with TGF β and other cytokines and is thus present in plasma and
body fluids. Peroxiredoxin 1 is now recognized as one of the pro 
inflammatory factors interacting with toll like receptor 4, which
triggers NF κB activation and other signaling pathways to evoke
inflammatory reactions. Some cancer cells release peroxiredoxin 1
to stimulate toll like receptor 4 mediated signaling for their pro 
gression. Interestingly, peroxiredoxins expressed in protozoa and
helminth may modulate host immune responses partly through
toll like receptor 4 for their survival and progression in host.
Extracellular peroxiredoxin 1 and peroxiredoxin 2 are known to
enhance natural killer cell activity and suppress virus replication
in cells. Peroxiredoxin 1 deficient mice show reduced antioxidant
activities but also exhibit restrained tissue inflammatory reactions
under some patho physiological conditions. Novel functions of
peroxiredoxins in inflammation, cancer and innate immunity are
the focus of this review.
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1. Introduction
Roughly two decades have passed since the cloning of peroxire-
doxins (Prxs).(1–4) Yamamoto et al.(1) selected a cDNA encoding
mouse Prx3 initially termed MER5 as a preferentially expressed
gene in erythroleukemia cells. Chae et al.(2) cloned a yeast
Saccharomyces cerevisiae peroxiredoxin termed thiol-specific
antioxidant (TSA), a previously characterized 25-kDa antioxidant
enzyme. Ishii et al.(3) cloned Prx1 initially termed MSP23 as one
of the major electophile- and oxidative stress-inducible proteins
from mouse peritoneal macrophages. In the same year, Prosperi
et al.(4) cloned human Prx1, designated PAG gene, as a highly
expressed gene in ras-transformed mammary epithelial cell line
HBL100. Additional researches in 1990s established the presensedoi: 10.3164/jcbn.11 109
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of TSA-like antioxidant family proteins among wide variety of
organisms, and it was proposed to call the family as peroxiredoxin
by Rhee and his group (reviewed in Rhee et al.(5)). Since then,
numerous studies have described unique properties of Prx family
proteins in various animals and plants. Previous studies estab-
lished that Prxs or thioredoxin peroxidases are important endo-
genous antioxidants, protecting cells from oxidative damage by
reducing H2O2 and peroxynitrite and scavenging thiyl radicals.(5–7)
Upregulation of some prxs in cells and tissues by various stress
agents is important biological response to cope with tissue dam-
ages.(8) As H2O2 generated in cells serves as an effector molecule
following binding of ligands to their membrane receptors, Prx’s
peroxidase activity is reversibly and effectively inactivated by
protein modification to transduce signals within cells.(9,10) It is also
known that some Prxs play a role as a chaperone in the form of
oligomers, the formation of which is enhanced under oxidative
stress conditions.(5,6,11) Godoy et al.(12) recently have studied a
detailed tissue localization of peroxiredoxin and thioredoxin (Trx)
family proteins in mouse by immunohistochemistry. A detailed
overview on the Prxs distribution will help to fully comprehend
their potential role in the various tissues.
The functions of Prxs are not restricted to their antioxidant
activities. Recent exciting discoveries include Prx1 (also termed
Prdx1 or PrxI) secretion from cancer or virus-infected cells(13)
and binding of both malarial parasite Prx(14) and Prx1(15) to the cell
surface alarm signal receptor toll-like receptor 4 (TLR4). These
reports have opened a door to explore the roles of Prxs in inflam-
mation and innate immunity. They also shed light on previous
findings that extracellular Prx1 and Prx2 enhance natural killer
cell enhancing activity,(16,17) transforming growth factor-β1 (TGF-
β1) enhances Prx1 secretion,(18) Prx1 binds to macrophage migra-
tion inhibitory factor (MIF)(19) and Prxs bind cyclophilins.(20,21)
These and other recent studies highlight extracellular Prxs as
modulators of inflammation in relation to pathogen infection,
tissue repair after damage and tumor progression. In most cases
extracellular Prxs function independently of their peroxidase
activity. The interaction of Prxs with alarm signal receptors TLRs
will be the most important aspects for the study of biological
functions of extracellular Prxs.
It is noteworthy that Prx1 and Prx2 function in nucleus and to
modulate gene expression. Prx1 associates with transcription fac-
tors such as NF-κB,(22) c-Myc(23) and androgen receptor (AR),(24,25)
affecting their activities to regulate gene expression. In addition to
its peroxidase activity, Prx1 in cytoplasm has anti-apoptotic
functions through direct or indirect interactions with the key
apoptosis regulators, ASK1,(26) p66Shc,(27) and GSTpi/JNK.(28)
Thus, in this review we highlight the recent discoveries of the
biological functions of Prxs, focusing particularly on the novel
roles of Prx1 and Prx2 in protection against cell death, infection,
immunity and cancer.
2. Prxs Protect Cells from Stress induced Death
Prxs protect cells and tissues from oxidative damage through
their peroxidase activities. Furthermore, Prx1 suppresses oxida-
tive stress-induced cell death through direct/indirect interactions
with different types of kinases and enzymes that play key roles
in regulation of cell death and/or apoptosis depending on cell
type and stimuli (Fig. 1). Prx2 also suppresses apoptosis signal-
regulating kinase 1 (ASK1) activation by reactive oxygen species
(ROS) through its peroxidase activity maintaining Trx in a reduced
state in neurons (Fig. 1).(29) Both electrophile- and oxidative-stress
activate expression of Prx genes.
2.1.  Prx1 suppresses ASK1 JNK signaling. ASK1 is a 
member of the mitogen-activated protein kinase family that
activates both JNK and p38 MAPK signaling cascades.(30) Under
non-stressed conditions, ASK1 is associated with its physiological
inhibitor, Trx.(31) Trx in its reduced form binds directly to the
N-terminal non-catalytic region of ASK1. The association of Prx1
with ASK1 was observed after the treatment of human embryonic
kidney 293 cells with 5 mM H2O2 for 20 min.(31) Prx1 interacts with
ASK1 via the thioredoxin-binding domain of ASK1, suggesting
that oxidized Prx1 exchanges with reduced Trx as the binding
partner after H2O2 treatment. Overexpression of Prx1 significantly
inhibits the phosphorylation/activation of ASK1 following H2O2
treatment. In Prx1 knockdown cells, ASK1, p38 and JNK are
rapidly activated, leading to apoptosis following exposure of cells
to 0.2 mM H2O2.(26) However, it is difficult based on these results
to estimate how much Prx1 binding to ASK1 contributes to
suppression of its activation following H2O2 treatment, since
Prx1 can eliminate H2O2 in cooperation with Trx.
Prx1 also suppresses JNK activation through an indirect
interaction with JNK in a peroxidase-independent manner.(28)
Glutathione S-transferase pi (GSTpi) is known to bind JNK and to
inhibit its activation induced by various stresses.(32) Interestingly,
Prx1 physically interacts with GSTpi and inhibits JNK release
Fig. 1. Multiple roles of Prx1 in suppression of oxidative stress induced
apoptosis. In addition to the Trx peroxidase activity to eliminate H2O2,
Prx1 cooperates with Trx in suppression of H2O2 induced activation of
the two apoptosis signal regulators, ASK1(26) and p66Shc,(27) through
direct interactions. The activation of ASK1 by oxidant stress is inhibited
by reduced form of Trx under low stress conditions. When human
embryonic kidney 293 cells were treated with 5 mM H2O2 for 20 min,
oxidized Trx was replaced by oxidized Prx1 to further suppress ASK1
activation.(26) Under low stress conditions, Trx and Prx1 maintain p66Shc
inactive, by keeping it reduced and dimeric form. Under high stress
conditions (1.47 mM H2O2), Prx1 is oxidized forming a decameric
chaperone and separated from p66Shc, which is phosphorylated at Ser 
36. JNK phosphorylates p66Shc at Ser 36,(38,39) inducing tetramer forma 
tion and translocation of p66Shc to mitochondria to generate ROS.(27,37)
On the other hand, ionizing radiation activates tyrosine kinase c Abl(41)
and JNK.(28) We speculate Prx1 may inhibit activation of c Abl following
ioning radiation. Prx1 indirectly binds JNK through GSTpi, which sup 
press activation of JNK.(28) Prx2 like Prx1 suppresses ASK1 activation in
neuronal cells in which Prx2 is highly expressed.(29) J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 93
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from the GSTpi-JNK complex following treatment of human
cancer 1170i cells with γ-ray radiation.(28) Prx1 overexpression in
cancer cells suppresses radiation-induced JNK activation and
apoptosis.(28) Since GSTpi catalyzes S-conjugation of glutathione
by electrophilic compounds, including carcinogen and anticancer
drugs, tumors overexpressing GSTpi seem to be drug-resistance in
chemotherapy in two ways. In case of Schizosaccharomyces
pombe, another role of Prx was shown in the activation of p38/
JNK homolog (Sty1) by peroxide treatment, where the formation
of a disulfide bond between Prx and Sty1 activated the kinase.(33)
2.2. Prx2 suppresses ASK1 activation in neurons.
Among prxs, Prx2 is the most abundant in mammalian neurons
and plays a protective role under oxidative stress.(29) Since Prx2
expression levels are significantly elevated in Parkinson’s disease
(PD) patient brains, Hu et al.(29) examined its protective role
against dopaminergic toxin 6-hydroxydopamine on neurons. It is
widely recognized in PD that dopaminergic neurodegeneration
occurres in the substantia nigra pars compacta due to activation
of the mitochondrial apoptotic pathways. Inactivation of Prx2
peroxidase activity either by S-nitrosylation through reaction with
nitric oxide at two critical cysteine residues(34) or by Cdk5-mediated
phosphorylation at Thr-89(35) are observed in human PD brains and
in PD models. Lentivirus-mediated Prx2 overexpression conferred
marked neuroprotection against 6-hydroxydopamine toxicity in
dopaminergic neuron cells and in mouse brain.(29) Prx2 exhibited
anti-apoptotic effects in dopaminergic neurons via suppression of
ASK1 activation. Prx2 overexpression maintained Trx in a reduced
state thereby suppressing ASK1 activation (Fig. 1).
2.3. Prx1  inhibits  p66shc activation. An adaptor protein
p66Shc is the only known pro-apoptotic member of the Shc protein
family.(36) It is a central player in stress-induced apoptosis through
induction of the respiratory burst and mitochondrial rupture.(36,37)
Prx1 was identified as one of the negative modulators of p66Shc
activation. Pull-down assays using resin-bound p66Shc identified
Prx1 as a binding partner with a high affinity in mitochondrial
extracts, which contained low levels of Prx1.(27) Prx3, the major
Prx in the mitochondrial matrix, did not exhibit affinity for p66Shc.
Prx1 associated with p66Shc and suppressed H2O2-generation via
p66Shc independent of its peroxidase activity. When cells were
treated with 5 mM H2O2, p66Shc was phosphorylated at Ser-36
inducing disassembly of the p66Shc-Prx1 complex, resulting in the
formation of a Prx1 oligomer. Subsequently, p66Shc translocates to
the mitochondrial compartment where it forms a tetramer, leading
to ROS generation through its interaction with cytochrome c and
induces apoptosis(37) (Fig. 1).
The phosphorylation of p66Shc at Ser-36 is key for its activation.
Phosphorylation depends on JNK activation induced by UV
irradiation in human neuroblastoma cells(38) or H2O2 treatment
(0.1 mM, 1 h) in bovine aortic endothelial cells.(39) In addition to
JNK, PKC-β phosphorylates p66Shc in embryonic fibroblasts
after treatment with H2O2 (0.5 mM, 10 min).(40) Thus, Prx1 could
suppress oxidant stress-induced activation of ASK1-JNK-p66Shc
signal pathway via multiple mechanisms (Fig. 1). It is worth
noting, however, that Trx inhibits both ASK1 and p66Shc activation
under basal conditions and that Prx1 plays auxiliary inhibitory
role under oxidative stress.
2.4.  Prx1 inhibits c Abl activation. Prx1 is known as a
physiological inhibitor of c-Abl tyrosine kinase activity.(41) The c-
abl gene was originally identified as the cellular homolog of the
transforming gene of the Abelson murine leukemia virus. This
kinase is one of the nonreceptor tyrosine kinases of the Src family
and ubiquitously expressed among tissues, with particularly high
levels in thymus, spleen, and testes.(42) Prx1 associates with the
SH3 domain of c-Abl and inhibits its kinase activity.(41) Although
c-Abl has many functions as cell cycle regulation,(42,43) an important
role of the kinase is regulation of double-strand breaks repair and
promotion of the cell death response following DNA damage.(44)
As c-Abl plays a crucial role in the apoptotic response to ionizing
radiation and other DNA-damaging agents and is known to
function as an upstream effector of the JNK and p38 MAPK
pathways,(45) we speculate that Prx1 may play a role in inhibiting
this cell death signaling pathway (Fig. 1).
2.5.  Upregulation of Prxs levels by stress. Induction of
prx1 gene activation is an important adaptive response to cope
with elecrtophiles and oxidative stress agents. Transcription factor
Nrf2 is the major positive regulator of prx1 gene expression by
wide variety of stress agents.(46) In addition to Prx1, Nrf2 regulates
upregulation of group of antioxidative enzymes and proteins such
as heme oxygenase-1 (HO-1), A170/sequestosome1/p62 and a
cystine transporter in mouse peritoneal macrophages.(46) Prx1
cooperates with these gene products to protect cells from insulting
agents. Nrf2 plays crucial roles in induction of the group of
detoxification enzymes by electrophiles through antioxidant/
electrophile responsive element in vivo.(47) Dietary 2(3)-tert-butyl-
4-hydroxyanisol, a synthetic phenolitic antioxidant and previously
used as a food preservative, enhanced Nrf2-dependent expression
of both Prx1 and GST in liver and epithelial cells of proximal
small intestine.(48)
Shiota  et al.(49) showed transcription factors Ets1 and Ets2
regulate upregulation of both Prx1 and Prx5 by H2O2 and hypoxia
in human prostate cancer PC3 cells and epidermoid cancer KB
cells. They treated cells either with 1 mM H2O2 for 30 min or
hypoxia (oxygen-free) for 4 h and afterward monitored expression
of Prx1 and Prx5 in the cells. Ets1 and Ets2 were also upregulated
by the stress and function through direct interaction with high-
mobility group protein 1 (HMGB1).(49) These transcription factors
may partly contribute in maintaining high Prx1 and Prx5 levels in
tumors.
Wang et al.(50) found that Prx5 is upregulated in degenerative
human tendon. Osteoarthritic cartilage expresses higher Prx5
levels compared to normal cartilage.(51) Their results show inflam-
matory cytokines TNF-α and IL-1β enhance Prx5 expression in
human cartilage tissue, suggesting Prx5 may play a protective role
against oxidative stress in human cartilage.(50) It is shown by others
that LPS-TLR4 signaling upregulates Prx5 expression in bone
marrow-derived macrophages.(52) Supplementing LPS (0.01 to
50 ng/ml) and IFN-γ (0.01 to 20 U/ml) respectively enhanced
expression of Prx5 mRNA and protein in the macrophages. The
prx5 gene activation depended on TLR4 and adaptor protein TRIF
but not on MyD88.(52) Experiments using MAPKs inhibitors
revealed that p38 and JNK mainly contribute to Prx5 upregulation
in immunostimulated macrophages.
3. Roles of Nuclear Prx1 and Prx2
Prx1 is localized in the nucleus as well as in the cytoplasm and
has been shown to interact with transcription factors such as c-
Myc, NF-κB and AR to modulate their activities (Fig. 2). The
effects of nuclear Prx1 on gene expression via c-Myc are espe-
cially important for elucidating the phenotype of Prx1-deficient
mice as will be discussed in later sections. Prx2 also localizes in
both the nucleus and cytoplasm to protect cancer cells from
chemotherapeutic agents.(51)
3.1. Prx1 binds with c Myc and modulates gene expres 
sion. Myc proteins are bHLH-ZIP transcription factors that bind
to their cognate genes in heterodimeric association with Max,
another bHLH-ZIP protein.(54,55) The c-Myc oncogene product
influences many cellular processes, including growth, cell cycle
progression, apoptosis, and differentiation. Prx1 interacts with
the c-Myc oncogene product through its highly conserved Myc
Box II (MBII) domain, which is critically important for transfor-
mation and transcriptional regulation.(56) Their physical interaction
was first shown in a yeast two-hybrid screen system and then by
immunoprecipitation. The number of both positive and negative
target genes of c-Myc is more than 1000, and it was shown that
Prx1 apparently suppresses regulation of some c-Myc targetdoi: 10.3164/jcbn.11 109
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genes and thereby suppresses tumor growth.(23,56) Over-expression
of Prx1 in 32D myeloid cells down-regulates some but not all
expression of the c-Myc MBII domain-dependent genes. In
embryonic fibroblasts from Prx1 deficient mice, altered expres-
sion of a subset of c-Myc target genes has also been observed.(23)
Enhanced expression of c-Myc in Rat1a cells enhanceds cell
colony formation in soft agar and tumor formation in explanted
mice. However, simultaneous expression of Prx1 and c-Myc in
these cells significantly suppresses the action of c-Myc,
suggesting a role for Prx1 as a tumor suppressor.(56)
Graves et al.(57) found that Prx5 expression level was roughly
5 times higher in Prx1 deficient embryo fibroblasts. It may due
to the fact that the gene expression of Prx5 partly depended on
c-Myc, of which activity was suppressed in the presence of
Prx1.(23,57)
3.2. Nuclear Prx1 enhances NF κB activity. Cytoplasmic 
Prx1 is known to suppress NF-κB activation by eliminating
peroxides,(58) but nuclear Prx1 enhances NF-κB activity by at
least two ways. In HeLa cells expressing nuclear localizing Prx1
(NLS-Prx1), stimulation with H2O2 (0.1–0.5 mM) enhanced NF-
κB activation 1.8–2.8-fold measured using a luciferase reporter
assay.(22) It was suggested that increased nuclear Prx1 inhibited
oxidation of the redox-sensitive cysteine in the DNA binding
domain of p50, the cleaved product of p105 (NF-κB1).(22) Another
study reported that nuclear Prx1 enhances p65-mediated cyclo-
oxygenase (COX)-2 gene expression in estrogen receptor (ER)
deficient human breast cancer cells (MDA-MB-231).(59) Prx1
expression levels in breast cancer cell lines were higher than in
normal or pseudonormal breast cell lines, and interestingly,
nuclear Prx1 levels were higher than cytoplasmic levels in these
cancer cells. In ER deficient cells, Prx1 was partially phosphory-
lated at Thr-90, which promoted oligomerization to enhance the
chaperone activity. This may due to enhanced Cdk2 activity,
which phosphorylates at Thr-90 and inactivates Prx1 peroxidase
activity. Under these conditions Prx1 interacted with NF-κB p65
and associated with the COX-2 gene upstream promoter region.(59)
In ER-positive MCF7 breast cancer cells, however, Prx1 was
neither phosphorylated and nor associated with the promoter
region. MCF7 cells may have reduced Cdk2 activity due to higher
expression levels of p27 and p21, intrinsic inhibitors of Cdk2,
compared to MDA-MB-231 cells.(60) These studies suggest nuclear
Prx1 could enhance NF-κB activation in ER deficient tumor cells
in which Prx1 phosphorylation is enhanced.
3.3. Effects of Prx1 and Prx2 on activation of androgen
receptor. Activation of AR plays a critical role in prostate
cancer development. Hypoxia/reoxygenation or synthetic androgen
treatment activates the AR in cultured prostate cancer cells, and
Prx1 acts as a key mediator as monitored using an AR-dependent
luciferase reporter assay.(24) Increased Prx1 expression enhanced
the AR action and Prx1 knockdown by short hairpin RNA
suppresses AR activity and decreases the growth rate of the
androgen-dependent cancer cells.(24) It was shown that hypoxia/
reoxygenation treatment induces oxidation of Cys-52 residue in
Prx1, which was associated with AR binding to the AR-element of
the prostate-specific antigen gene.(24) The antioxidant activity of
Prx1 was not necessary for its AR stimulatory function. The
association of Prx1 with AR significantly increased the affinity
of AR for dihydrotestosterone.(25) These studies suggest that
disrupting the interaction between Prx1 and AR may serve as a
target in the management of prostate cancer (Fig. 2).
Prx2 also modulates AR transactivation in prostate cancer
cells.(61) Compared to human prostate cancer LNCaP cells, the
expression levels of Prxs were higher in both castration-resistant
derivatives LNCaP-CxR and H2O2-resistant derivative LNCaP-
HPR50 cells. Among the prxs, Prx2 expression was markedly
increased in the prostate cancer cells. Overexpression of Prx2
increased AR transactivation, whereas overexpression of nuclear-
localizing Prx2 suppressed AR transactivation (Fig. 2). The
nuclear localization of Prx2 was reduced in LNCaP-CxR cells
compared with LNCaP cells. Downregulation of Prx2 with
Fig. 2. Roles of nuclear Prx1 and Prx2. Prx1 is localized in both the cytoplasm and nucleus and interacts directly with the transcription factors, c 
Myc,(56) NF κB(22,59) and AR.(24) Prx1 suppress c Myc,(23,56) whereas it enhances activities of p50(22) and p65(59) components of NF κB and helps activation/
phosphorylation of AR.(24) Prx2 is also localized in the nucleus and enhances JNK signaling induced by anticancer/DNA damaging agent resulting in
DNA repair and tumor survival.(53) Cytoplasmic Prx2 increases AR transactivation, whereas nuclear Prx2 suppresses AR transactivation. J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 95
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siRNA reduced growth of LNCaP-CxR cells.(61)
3.4. Nuclear Prx2 protects cancer cells from DNA 
damaging agents. Treatment of cancer cells with chemothera-
peutic or DNA-damaging agents like etoposide induces necrotic
cell death. It was shown that down-regulation of Prx2 by siRNA in
cancer cells results in increased cell death and sensitivity to these
agents, suggesting Prx2 facilitates tumor survival.(53) Further
characterization revealed Prx2 is present in nucleus and enhances
agent-induced activation of the JNK/c-Jun pathway involved in
repair of damaged DNA.(53) Prx1 knockdown in HeLa cells did not
show any effect in this assay system. Prx2 knockdown in other
cancer cell lines such as HCT116 and U2OS induces similar
effects as in HeLa cells, but it did not cause any significant effect
in normal fibroblasts. Peroxidase activity of Prx2 is unlikely to be
involved in the protection of cancer cells from DNA-damaging
agents.
4. Biological Functions of Extracellular Prxs
In addition to Prx4,(7) Prx1 is also secreted from cells. Other
Prxs are also detected in body fluids, suggesting they also function
in extracellular space. Biological functions of extracellular Prxs
are interesting subjects for future studies especially in regulation
of inflammation. TLRs may be key molecules in their biological
functions. Interaction of parasite Prxs with host TLR4 is important
in respect to both self-defense and infection. Physiological
importance of interaction between Prx1 and MIF or cyclophilin A
has not been established yet.
4.1. Presence of Prxs in body fluids. Prxs are present in
various extracellular body fluids. Bronchoalveolar lavage fluid
(BALF) contains many proteins, which represents a unique
clinically useful sampling of the lower respiratory tract. Guo
et al.(62) and Gharib et al.(63) performed proteomic analysis of
unique proteins contained in mice and human BALF and detected
Prx1, Prx5 and Prx6 among them. Interestingly, the increased
level of Prx1 in BALF was observed in many patients with acute
lung injury compared with normal subjects.(63)
The interstitial fluid of bone marrow, a pivotal component of
the hematopoietic niche, includes all the extracellular cytokines
between the cells of bone marrow and constitutes the external
microenvironment of the bone marrow stromal cells. Wang et al.(64)
analyzed differentially expressed fluid proteins and identified
Prx2 as one of the proteins down-regulated during aging. They
suggested Prx2 is produced by stromal cells like other soluble
factors and might be secreted. They speculated that decrease in
Prx2 expression might cause increase in intracellular H2O2 levels
in the cells of aged mice.
4.2. Prx1 secretion from mammalian cells. Recent studies
have established the secretion of Prx1 from cells. Although the
precise mechanism underlying its secretion is not known, different
cultured cells have been shown to secrete Prx1 following
stimulation with some cytokines such as TGF-β1,(18) IL-1 and
oncostatin M,(65) a subfamily of IL-6. Prx1 is detected in plasma
and various tissue fluids and seems to play a key role in
modulating inflammation, immunity and tissue repairing reactions
in vivo partly through its interaction with the cell surface sensor
TLR4 (Fig. 3).
Chang et al.(66) reported that non-small cell lung cancer tissue
expresses high levels of Prx1. Nearly half of the cancer-bearing
patients had autoantibodies to Prx1 and about one-third of them
had immuno-detectable Prx1 in their sera, suggesting Prx1 was
secreted from the lung cancer tissue.(13) These studies suggest the
Prx1 secretion could be used as potential lung cancer biomarker or
as a criterion for cancer typing. They found that cultured lung
adenocarcinoma cells (A549) secrete Prx1, but non-cancer lung
cells (BEAS 2B) do not secrete Prx1(13) and that Prx1 secretion
from A549 cells was largely dependent on TGF-β1 and was not
associated with cell lysis or death.(18) It was shown that A549 cells
expressed higher TGF-β1 mRNA levels and converting enzyme
activity to produce its active form.(18) Other cancer cells as MCF7,
Hep3B and HeLa do not secrete Prx1 via TGF-β1,(18) indicating
that Prx1 secretion may be cell-type specific. Since Prx1 lacks a
signal peptide for the classical or ER/Golgi-dependent secretory
pathway, its secretion from cells may be mediated through the
non-classical secretory pathway like other proteins such as IL-1,
MIF, Trx and Hsp70. It seems important to further characterize
the biological role of Prx1 secretion induced by TGF-β since it is
a released from blood platelets and various stromal components
(reviewed in Massague et al.(67)).
Prx1 secretion was also observed from primary human articular
chondrocytes.(65) To analyze the secretion, the chondrocytes were
cultured to pre-confluence and changed to serum-free medium, and
stimulated with either IL-1 (1 ng/ml) or oncostatin M (10 ng/ml)
for 24 h. The proteins in the medium were separated by 2D gel
electrophoresis and the spot of Prx1 was identified. Prx1 was one
of several major proteins found in the medium after treatment
with these cytokines.(65) This result suggests a role of Prx1 in the
maintenance of cartilage tissue.
4.3. Binding of Prx1 and malarial Prx to TLR4. The find-
ings that both Prx1(15) and malaria parasite derived Prx(14) bind
cell surface danger signal receptor TLR4 opens a new field to
investigate novel roles of extracellular Prxs in inflammation and
innate immunity. Riddell et al.(15) found extracellular Prx1 binds
to TLR4 and acts as a pro-inflammatory factor. Supplementing
Prx1 (about 50 μg/ml) to culture medium stimulated TNF-α and
IL6 secretion from thioglycollate-elicited murine macrophages or
immature bone marrow-derived dendritic cells.(15) This reaction is
mediated through TLR4, a major cell surface receptor resulting
in inflammatory response in an MyD88-dependent fashion. Cell
Fig. 3. Prx1 is secreted from cells and activates TLR4 mediated
signaling. Cytokines such as TGF β,(18) IL 1 and oncostatin M(61) enhance
Prx1 secretion from cells although precise mechanism is unknown. Prx1
binds TLR4 that regulates intracellular signaling to activate NF κB,
which induces production of various cytokines important in inflamma 
tion, immunity and tissue repair reactions.(68)doi: 10.3164/jcbn.11 109
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surface TLRs recognize foreign pathogens as LPS and also various
endogenous host molecules that trigger inflammatory and repair
responses. Most of these host molecules are produced either as a
result of cell death or injury. These include degradation products
of the extracellular matrix, heat-shock proteins and HMGB1
proteins (reviewed in Kawai and Araki(65)).
4.4. Interaction of Prx1 with MIF. Association of Prx1 with
MIF has been reported in transformed human kidney embryonic
fibroblasts, 293T cells.(19) The direct binding was first found in a
two-hybrid system and further characterized by immunoprecipita-
tion using cell extracts and their recombinant proteins.(19) MIF
forms a homotrimer (3 × 12.5-kDa) and possesses a tautomerase
activity for which physiological substrates have not been
identified. Prx1 binds MIF through a disulfide bond using its
conserved Cys-173 and partially inhibits the tautomerase activity
of human recombinant MIF. It is also evident that MIF inhibits
the peroxidase activity of Prx1 in the associated form. However,
the biological role of Prx1 association with MIF remains to be
elucidated.
MIF is a pro-inflammatory factor originally identified more
than 40 years ago as a T-cell-derived factor responsible for the
inhibition of macrophage migration in delayed-type hyper-
sensitivity.(69,70) Various studies have established that it helps
tumor growth and plays a central role in the host immune and
inflammatory response (see recent reviews by Conroy et al.(71) and
Noels et al.(72)). It is expressed in various cells including lympho-
cytes, macrophages, epithelial cells and endothelial cells.(71,72) In-
tracellular MIF affects signaling to suppress apoptosis but secreted
MIF from cells acts like cytokines through its receptors. MIF acts
to modulate and amplify the response to LPS at least partly by
upregulation of TLR4 expression.(73,74) LPS administration in vivo
promotes secretion of MIF into plasma causing enhanced inflam-
mation. Many other factors as H2O2 (100 μM) and hypoxia also
enhance MIF expression and secretion.(75) Although there is no
published evidence, it is reasonable to assume extracellular Prx1
could associate with secreted MIF causing suppression of MIF-
mediated enhancement of inflammation.
4.5. Interaction of Prxs with cyclophilin A. Cyclophilin A
(CyPA) is a regulator of inflammation and bind to immuno-
suppressant cyclosporine A like other cyclophilin family proteins.
CyPA is a ubiquitously and abundantly expressed protein having
peptidyl-prolyl  cis-trans isomerase activity. Lee et al.(21) first
identified CyPA as Prx6 binding protein using rat lung crude
extracts. They found that CyPA binds to all Prx1 to Prx6 mamma-
lian Prxs and enhance their thiol-specific antioxidant activity.
The reaction mixture of the assay system contains 10 mM
dithiothleitol (DTT) and 3 μM FeCl2, which produces thiyl
radicals by iron-catalyzed autoxidation of DTT causing inactiva-
tion of glutamine synthetase. Prxs protect the target protein by
scavenging thiyl radicals, and oxidized Prxs are reduced to
reactive form by excess DTT in the absence of intrinsic Prx
reducing system, Trx/Trx reductase/NADPH. CyPA seems to
facilitates reduction of Prxs in the presence of DTT, although
precise mechanism is not known. Jaschke et al.(20) also showed
that human T cell cyclophilin18 binds to yeast Prx and enhanced
its thiol-specific antioxidant activity.
CyPA is secreted from vascular smooth muscle cells (VSMCs)
by a vesicular pathway under oxidative stress and mediates
vascular remodeling by promoting inflammation and VSMC
proliferation.(76) Extracellular CyPA binds its receptor CD147 and
activates ERK1/2, Akt and JAK, which promotes chemotactic
activity towards a variety of immune cells.(77) CyPA is upregulated
in a variety of inflammatory conditions, such as rheumatoid
arthritis, autoimmune disease, and cancer. Interestingly, both
CyPA and Prx1 are secreted from human articular chondrocytes
by stimulation with either IL-1 or oncostatin M.(65) CyPA coexsists
with Prx1, Prx5 and Prx6 in bronchoalveolar lavage fluids
(BALFs) of mice.(62,63) These results suggest both Prxs and CyPA
may mutually affect their functions and modulate inflammatory
reactions in extracellular space.
4.6. Effects of Prx1 and Prx2 on virus replication.
Geiben-Lynn et al.(78) found Prx1 and Prx2 were preferentially
upregulated in bulk CD8+ T-cells from HIV seropositive
indivisuals compared to with seronegative individuals. They
found an interesting phenomenon that plasma levels of the
NKEKs were elevated (up to 500 ng/ml) in 3 of 13 HIV-infected
but untreated persons and that exogenous Prx1 and Prx2 inhibited
virus replication in human T-cells.(78) Supplementing recombinant
Prx1 or Prx2 to culture medium respectively inhibited HIV-1
replication in the cells at an ID50 (dose inhibiting HIV-1 replica-
tion by 50%) of –130 nM (3 µg/ml). Supplemented Prx1 (3 µg/ml)
also inhibited replication of dual-tropic simian immunodeficiency
virus and dual-tropic simian-human immunodeficiency virus.
Both Prx1 and Prx2 were detected in the culture medium of CD8+
T-cells at 15–40 ng/ml after 4 h, regardless of whether the cells
were stimulated with anti-CD3 and whether the cells were from
HIV-1 infected or uninfected individuals. The concentration of
Prx1 in the medium reached up to –125 ng/ml at 16 h, however,
this concentration was below that causing significant inhibition of
HIV-1 replication. When Prx1 or Prx2 were over-expressed –10-
fold in Jurkat CD4+ T-cells, the HIV-1 replication was inhibited
after 5 to 8 days by 80–98%. Notably, the inhibitory effect
appeared only several days after virus infection, which meant
stably expressed high levels of intracellular Prxs could not inhibit
virus replication at the early infection stage. Although these
authors suggested that intracellular Prx1 and Prx2 blocks virus
replication through down-regulation of the NF-κB pathway,(78) it is
more likely that secreted Prx1 and Prx2 gradually accumulated in
the medium and inhibit virus replication within cells.
Another study shows cytoplasmic Prx1 enhances the RNA-
dependent RNA polymerase activity (i.e., transcription and
replication) of the lymphotropic measles virus in HEK293-SLAM
cells.(79) It was shown Prx1 binds to the C-terminal region of the
nucleoprotein (NTAIL) of the virus and enhance RNA synthesis
of the virus in the cells.
4.7. NK cell enhancing activity of Prx1 and Prx2. Natural 
killer cell enhancing factor (NKEF) was first identified in
erythrocyte cytosol.(16) This study initiated from the observation
that intact red blood cells (RBCs) supplemented to assay medium
significantly enhanced natural killer cell-mediated cytotoxicity to
cancer cells. Since cytosol proteins from RBCs also augmented
the NK activity to kill human erythroleukemic cell K562, the
active protein component was isolated and partially sequenced.
Two cDNA clones encoding NKEF-A and -B, respectively
corresponding to Prx1 and Prx2, were isolated from K562 cells.
Both NKEF-A and -B recombinant proteins augmented NK
cytotoxicity, but they did not enhance lymphokine-activated
killer cytotoxicity.(17) Active RBC NKEF (NKEF-B/Prx2) has
an apparent molecular mass of between 300 and 400 kDa,(16)
suggesting it exists as oligomers. The recombinant Prx2, pre-
treated with dithiothreitol, which might inhibit oligomerization,
hardly enhanced cytotoxicity of NK cells.(17) Blocking sulfhydryl
residues in NKEFs with N-ethylmaleimide, inhibits either dimer
or oligomer formation and diminishes activity. These results
show exogenously added Prx1 and Prx2 in the form of oligomer
could enhance NK activity, although the underlying mechanisms
remain to be elucidated. The NK cell enhancing activity of Prx1
and Prx2 is now regarded as an important immunological activity,
since Prx1 can be secreted from some tumors and both Prx1 and
Prx2 are released from virus-infected CD8+ T cells(78) and Prx2 can
be released from RBC following hemolysis.
We propose a potential mechanism by which exogenous Prx1
and Prx2 could enhance NK cell killing activity (Fig. 4). Prx1 and
Prx2 may act through TLR4 in NK cells, since these cells also
express a functional TLR4/MD2 complex and can produce type 1
chemokines and IFN-γ upon stimulation,(80) which may result in J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 97
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enhancement of killing activity. It is reasonable to assume that
Prx2 also binds TLR4 similar to Prx1 due to their sequence
homology. Another possibility worth examining is the inhibition
of MIF activity by Prx1. MIF is known to suppress NK cell
activity through down-regulation of NK cell receptor NKG2D,
a key player for signaling of the perforin-mediated cytolytic
response,(81) which results in inhibition of release of perforin
granules from NK cells.(82) MIF is also important for maintaining
TLR4 expression levels.(74) MIF is ubiquitously expressed, and it
is released from both NK cells(83) and their target corneal endo-
thelial cells(59) and human uveal melanoma cells.(84) MIF is also
contained in serum, which is an essential component of the NK
cell activity assay system.(16,17) These results suggest that extra-
cellular Prx1 could enhance NK cell-mediated lytic activity
through inhibition of MIF activity, a concept consistent with the
fact that Prx1 has stronger NKEF activity compared to Prx2,(17) for
which binding to MIF has not been shown.
5. Parasite Prxs in Infection and Immunity
Parasitic protozoa and helminths have different strategies to cope
with host immune attack for their survival. Parasitic peroxire-
doxins play important roles for their protection against oxidative
damages and also for interaction with host immune systems.
5.1. Malarial plasmodium Prxs. Protozoan parasite plasmo-
dium faciparum, that cause tropical malaria, is a rapidly multi-
plying unicellular organism undergoing a complex developmental
cycle in man and mosquito. Malaria parasites are subjected to high
levels of oxidative stress during their development inside
erythrocytes. Malaria plasmodium, which lacks genuine catalase
and glutathione peroxidase, depends largely on Prxs for their
survival in erythrocytes.(85–87) Kawazu et al.(88) first cloned a
Prx6-like 1-Cys peroxiredoxin in plasmodium (called Pf-1-Cys-
Prx), of which content is roughly 0.5% of the total proteins in the
late trophozoites. Malaria plasmodium also expresses a Prx2-like
2-Cys Prx (PfTPx-1)(89–91) and another 2-Cys Prx (PfTPx-2), of
which peroxidase activity, however, has not been proven.(87)
Additionally, it has a Prx5-like atypical Prx termed PfAOP,(91) and
a glutathione peroxidase-like thioredoxin peroxidase (TPxG1).(85,93)
TPx-1 and 1-Cys-Prx mainly localize in cytoplasm, TPx-2 in
mitochondrial, and AOP in apicoplasm.(85,87,93) TPxG1 localizes in
both cytoplasm and apicoplast.(93)
In addition to these 5 peroxiredoxins, plasmodium has an
unusual peroxiredoxin renamed PfnPrx (earlier called MCP1)
which has a broad substrate specificity using both thioredoxin
and glutaredoxin as reductants.(94) It localizes to the nucleus and
is associated with chromatin, suggesting a role in the protection
of nuclear DNA against oxidative damages.(94)
5.2. Host immune reaction to malaria plasmodium.
Malaria parasites have devised many strategies to escape the
host’s immune response and to survive in the host. It has been
reported that malarial parasite infection increases production of
IgE, which plays a protective role against malarial infection.(14) In
the infection experiments of Plasmodium berghei ANKA to mice,
IgE produced in mouse sera detected the parasite Prx as a major
antigen among 65 separated parasite’s proteins.(14) The infection of
Plasmodium falciparum induces elevation in immune mediators
such as inflammatory interleukins, TNF and NO in human and
animal. Among the mediators, high concentrations of TNF,
mainly produced by mast cells, were shown to be associated
with disease severity.(95) They searched parasite-produced TLR4
agonists, since TNF production mainly depends on TLR4/MD-2
mediated activation of the transcription factor NF-κB, and
identified the malarial parasite PfTPx-1, a Prx2-like peroxiredoxin,
as a TLR4 agonist leading NF-κB activation.(14) These studies first
established the novel function of parasite-derived Prx in innate
and acquired immune responses in malarial parasite infection.
5.3. Incorporation of erythrocyte Prx2 into plasmodium.
Koncarevic et al.(96) recently reported an interesting finding that
malaria Plasmodium imports erythrocyte Prx2, thereby using the
host protein for its protection. Notably, human Prx2 accounts
for roughly 50% of thioredoxin peroxidase activity in parasite
extracts. Treatment of plasmodium-bearing erythrocytes with
chloroquine, a drug promoting oxidative stress, increased the
content of human Prx2 in parasite cytoplasm.(96) They denied a
possibility that transported Prx2 is directed to the food vacuole,
where erythrocyte cytoplasmic proteins including hemoglobin
are digested. The specific-incorporation of Prx2 and three other
rafts-localized host proteins into intracellular parasitophorous
vacuolar membrane formed by merozoite was previously charac-
terized.(97) Interestingly, Prx2 is also localized in Mauer’s clefts,(96)
which are membranous structures used by the parasite for protein
sorting and protein export.(98) In the case of malaria parasite
infection, we speculate that host Prx2 may be released from either
erythrocyte upon hemolysis or protozoa through Murer’s clefts
resulting in competition between Prx2 and malarial Prx for
modulating host immune reaction. Further studies are warranted to
clarify the functional differences, if any, among Prx1, Prx2 and
parasites Prxs in modulation of host immune reactions against
parasites.
5.4. Prxs in helminth infection. Parasitic nematodes express
high levels Prxs that are assumed to play a pivotal role in dealing
with both internal and external oxidative stress since they lack
selenium-containing glutathione peroxidase (see review by
Henkle-Duhrsen and Kampkotter(99)). The 2-Cys Prxs have only
10% sequence identity with mammalian 2-Cys Prxs.(99) Both 1-
Fig. 4. A hypothetical mechanism how NKEF A and  B (Prx1 and 2)
could enhance NK cell activity. Prx1 has stronger NK cell enhancing
activity than Prx2.(17) Prx1 and presumably Prx2 bind TLR4 expressed on
NK cells inducing activation of NK cells through production of
chemokine and IFN γ.(80) It is also possible that Prx1 binds to MIF and
inhibits its activity. MIF can be released from target cells and is
contained in serum, resulting in down regulation of NKG2D expres 
sion,(81) a receptor important for perforin mediated cytolytic response.
This effect might be restricted to Prx1 since binding of Prx2 with MIF is
not shown.doi: 10.3164/jcbn.11 109
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Cys and 2-Cys Prxs are released from nematodes.(99–101)
Parasitic helminths have a striking feature for their ability to
elicit protective immunity and to persist within the host for long-
term. Helminths are known to secrete a variety of molecules
such as Prx, proteinases and their inhibitors, and cytokine homo-
logues that help them to penetrate the defensive barriers and avoid
the immune attack of the host.(101,102) Recent studies have estab-
lished that secreted helminth Prx modulates the immune responses
of their hosts in a manner independent of its antioxidant
activity.(100,103–105) The recombinant parasite Prx directly stimulates
macrophages to develop into alternatively activated phenotype, of
which macrophages are assumed to induce the differentiation of
naïve T cells to Th2 phenotype resulting production of high levels
of IL-10 and IL-4.(100,105) The macrophages activated by helminth
Prx suppressed the development of Th1 cells (IFNγ production)
without affecting the promotion of the differentiation of Th2
cells (IL-4 production) from naïve CD4+ T cells in the develop-
ment of antigen-specific Th2 immune responses.(105) Interestingly,
recombinant murine Prx2 also induces the marker gene Ym1
expression in macrophages and promotes polarized Th2 immune
responses,(105) an effect is apparently different from that of Prx.(15)
It is not clear at present how nematode Prx act through macro-
phages and whether or not they interact with TLRs.
Although further studies are required, above results suggest that
murine Prx1 and malarial Prx (PfTPx-1) promote polarized Th1
immune responses to produce inflammatory cytokines, and Prx2
and helminth Prx promote polarized Th2 immune responses to
produce anti-inflammatory cytokines or induce M2/wound-healing
macrophages under the employed experimental conditions. Based
on these results we suggest that the helminth parasites secrete Prx
to counteract host Prx1 function, thereby shifting the Th1/Th2
balance in the surrounding microenvironment beneficial for their
survival.
6. Roles of Prxs in Tissue Inflammation
Inflammation reactions are self defense response and provoked
following tissue injury and infection. Oxidative stress is involved
in the reactions and Prxs play important and complex roles in the
process of inflammation. Since different type of cells and various
regulatory factors are involved in a time-dependent manner during
the complex inflammation reaction, model mice deficient in each
Prx provide their physiological roles, which may not be observed
in single cell culture system.
6.1. Role of Prxs in lung protection. Prxs play important
roles in protection of lung, which is always facing danger of
infection and tissue oxidative damages by oxygen and various
insulting agents in the air. The pulmonary system has acquired
endogenous defenses such as antioxidant system, innate immunity,
drug detoxification and tissue repair systems to cope against these
attacks. Prx family proteins are expressed in a cell-type specific
manner in pulmonary tissue.(106) Bronchial and alveolar epithelial
cells express Prx1, 2, 3, 5 and 6 and alveolar macrophages express
Prx1, 3, 4, 5 and 6 at relatively high levels, respectively.(106)
Prx6, having non-selenium glutathione peroxidase activity, is
also known as a lysosomal-type acidic, Ca2+-independent
phospholipase A2 and plays important role in lung surfactant
dipalmitoylphosphatidylcholine degradation and synthesis.(107)
Prx6-deficient mice have increased sensitivity to hyperoxia,(108)
while transgenic mice overexpressing Prx6 have an increased
defense to hyperoxia.(109) Additionally, Prx1, 2, 4, 5 and 6 have
been detected in bronchoalveolar lavage fluid, suggesting their
roles in airway space in lung protection.(62,63)
Bleomycins, products of Streptomyces verticillis, have potent
tumor killing properties. However, a major adverse effect is
pulmonary toxicity. The toxicity of bleomycin is not restricted
to its effect on DNA but production of reactive oxygen species
through interaction with iron.(110,111) We recently compared the
bleomycin-induced acute lung injury and pulmonary fibrosis
between Prx1-deficient and wild type mice.(112) We showed
administration of bleomycin induced enhanced inflammation
and fibrosis in Prx1-deficient mice, suggesting Prx1 protects
cells from the acute oxidative damage by reactive oxygen species.
The enhanced pulmonary inflammation and fibrosis in Prx1-
deficient mice was partly inhibited by administration of N-acetyl-
L-cysteine.(112)
In another study, we have obtained results suggesting Prx1 is
involved in regulation of allergen-related airway inflammation.
Prx1 deficient mice exhibited an enhanced response to Th2
adjuvant (ovalbumin + aluminum potassium sulfate) but a sup-
pressed response to Th1 adjuvant (ovalbumin + complete Freund’s
adjuvant).(113) The Th1 adjuvant challenge in Prx1 deficient mice
lung caused reduced infiltration of eosinophils and neutrophils
into bronchoalveolar lavage fluid, suggesting a positive role of
Prx1 in the LPS-induced inflammatory reaction.(113)
6.2. Role of Prx1 in ozone induced lung inflammation.
Ambient O3 is a commonly encountered environmental air
pollutant. Since O3 is chemically reactive gas, it preferentially
induces oxidation of endogenous unsaturated lipids present in
pulmonary surfactant.(114,115) It is assumed that the secondary
ozonation products, such as lysophospholipids, aldehydes and
epoxycholesterol, mediate various cellular responses induced by
O3.(114,116,117) We recently found that O3 exposure (6 h, 2 ppm)
induced significantly less lung inflammation in Prx1 deficient mice
compared to WT mice monitored after 24 h. In bronchoalveolar
lavage fluids (BALF), infiltrated immune cell numbers and
protein levels of proinflammatory cytokines were significantly
less in Prx1 deficient mice compared to WT mice (Yanagisawa
et al., unpublished results).
Recent studies established that the biological response to O3 is
dependent on complex interaction with innate immune signaling
(reviewed in Al-Hegelan et al.(118) and Hollingsworth et al.(119)).
The endotoxin receptor, TLR4 significantly contributes O3-induced
lung hyperpermeability(120) and airway hyperresponsiveness
(AHR).(117) It was suggested that TLR4-dependent signaling could
lead to MyD88-dependent activation of NF-κB and generation
of downstream proinflammatory factors leading to AHR.(121,122)
TLRs 2 and 4 play important role in initiation of inflammation and
following tissue repair reaction.(123) We detected Prx1 in BALF
from WT mice both before and after O3 inhalation, suggesting
Prx1 is steadily secreted into the alveolar space even without any
injury.(114)
Our results suggest that alveolar Prx1 may be one of the
intrinsic activators of TLR4 signaling upon airway injury by O3
inhalation. Notably, low molecular weight hyaluronan (LM-HA)
fragments are released from the extracellular matrix in the early
O3-induced biological responses in mice lung and has been
identified as one of the TLR4 ligands.(118,123–126) We speculate LM-
HA and other factors such as platelet-activating factor(127)
produced under the tissue-damaging conditions may cooperate
with Prx1 in activation of TLR4 following ozone inhalation.
Since, pulmonary innate immunity is dependent on a complex
signaling network between many cell types,(128) further careful
studies are required to clarify the exact roles of Prx1 in ozone-
induced lung inflammation.
6.3.  Role of Prx1 in sensitivity to cisplatin. A major 
toxicity of the cancer chemotherapeutic agent cis-diamminedi-
chloroplatinum (II) (cisplatin) is acute renal failure. The toxicity
of cisplatin is partially associated with increased oxidative stress
and the protective role of Prx1 against its toxicity can be observed
in cultured cells. Mouse embryo fibroblasts (MEFs) derived from
Prx1-deficient mice showed increased cisplatin-induced apoptosis
compared with wild-type MEFs.(129) Cisplatin treatment led to
increased activation of p38 MAPK and JNK in Prx1-deficient
MEFs compared with wild-type MEFs. A JNK-specific inhibitor
protected the Prx1-deficient MEFs from cisplatin-induced J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 99
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apoptosis, suggesting a role of JNK activation in the induction of
apoptosis.(129) The above cell protection activity of Prx1 against
cisplatin/ROS-mediated apoptosis is in accord with the anti-
apoptotic activity of cytoplasmic Prx1 as shown above (Fig. 1).
However, in contrast to an in vitro cell study, Prx1 deficient
mice show significant resistance to acute renal damage caused
by cisplatin administration (Okada et al., unpublished data). We
suggest two possible reasons to elucidate the cisplatin resistance
in Prx1 deficient mice. The first reason is that the Prx1 deficient
mice have a higher clearance rate of cisplatin from blood
compared to wild-type mice. We found that Prx1 deficient mice
had higher expression levels of membrane transporters for
metabolites such as Mrp4 in kidney. Enhanced renal cisplatin
clearance through Mrp2 and Mrp4 across the brush border
membrane into the urine reduces the accumulation of cisplatin in
the plasma and proximal tubule cells, and results in reduced
nephrotoxicity.(130) It is shown the upregulation of c-Myc activity
induces increase in expression of membrane transporter genes in
human epithelial cells.(131) The enhanced expression of membrane
transporters in kidney may be due to enhanced c-Myc activity in
the Prx1 deficient mice.(23)
The second reason for cisplatin resistance in Prx1 deficient
mice may be defects in Prx1-TLR4 signaling. This idea is
consistent with the fact that cisplatin nephrotoxicity in mice is
largely mediated through parenchymal TLR4 signaling and that in
TLR4 deficient kidney, neutrophil infiltration, increase in IL-6,
keratinocyte chemoattractant and TNF-α were minimal after
cisplatin administration.(132)
7. Promotion of Tumor Growth by Prxs
Recent studies show Prxs expressed in tumor cells play positive
roles in their progression and/or metastasis in transplanted animals.
Different functions of Prxs are required for their progression/
metastasis in vivo depending on tumor types.
7.1. Prx1 enhances tumor progression. Human Prx1 or
Pag (proliferation associated gene) was originally cloned from ras
oncogene-transformed mammary-epithelial cells.(4) Prx1 expres-
sion is elevated in various cancer tissues and cancer cell lines that
are apparently linked with poor clinical outcomes and diminished
overall patient survival.(133–137)
A recent study shows Prx1 enhances growth of prostate cancer
cells through TLR4 signaling.(138) The Prx1 expression levels
increased in prostate cancer tissues during progression in model
mouse in vivo. Prostate cancer cells, human PC-3M and murine
C2H, were respectively inoculated into mice and time-dependent
increase in tumor volume was measured with calipers.(138) Down-
regulation of cellular Prx1 expression levels with shRNA treat-
ment before inoculation caused significant delay in PC-3M and
no growth in C2H tumors in vivo. The results suggest Prx1 expres-
sion within the tumor cells plays a role in its progression in vivo.
When Prx1-expressing C2H cells were inoculated into mice
deficient in TLR4 signaling, tumor did not grow. These results
show both Prx1 in the cancer cells and TLR4 in the host are
required for the tumor growth in vivo. Their results further
suggested that the Prx1-TLR4-MyD88 signaling, which actually
occurs in both tumor and host, contributes to expression of VEGF,
TNFα, IL-6, TGF-α and TGF-β within solid tumors and to
vasculature formation and function. They concluded that the Prx1-
TLR4 system plays a critical role in tumor growth by enhancing
vascular endothelial cell recruitment or migration through VEGF
production(138) (Fig. 5).
It is noteworthy that functional TLR4 is expressed in various
tumors and its activation promotes production of immuno-
suppressive cytokines and chemokines such as TGF-β, VEGF
and IL-8.(139) The TLR4-mediated signaling makes tumor cells
more resistance to lysis mediated by NK cells,(140) and to apoptosis
by anti-cancer drug,(141) TNF-α and TRAIL.(139) The study by
Fig. 5. Roles Prx1 and Prx6 in tumor progression and metastasis
through TLR4 MyD88 signaling. Cancer cells secrete Prx1 and activate
TLR4 MyD88 signaling in cancer and normal cells to help progression in
host.(138) Prx6 also helps growth and metastasis of cancer cells through
its GSH peroxidase and phospholidase A2 activities.(145,152) We suggest
a cooperation of extracellular Prx1 and cytoplasmic Prx6 in tumor pro 
gression through TLR4 MyD88 signaling (see text).
Fig. 6. Prx1 TLR4 signaling may be affected by other ligands of TLR4.
Recent studies have established that Prx1(15) and malaria parasite Prx(14)
are ligands of TLR4. Although there is no evidence, Prx2 may also bind
TLR4. Nematode Prx, having a low structural similarity to mammalian 2 
Cys Prxs, might also bind to TLR4. Functional interactions through TLR4
among Prxs and Prxs with other key inflammatory modulators including
LM HA, Hsp70 and LPS will be important subjects for future research
(see text).doi: 10.3164/jcbn.11 109
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Riddle et al.(138) first showed that Prx1 is one of the TLR4 ligands
utilized by cancer cells for their progression through TLR4
signaling. It is important to note, however, that small hyaluronan
fragments are also known to contribute tumor development
through TLR4 mediated signaling (see reviews by Lokeshwar and
Selzer(142) and Girish and Kemparaju(143)). In human cancers,
hyaluronan contents are usually higher in tumors than in normal
tissues and hyaluronidase-1 is the main degrading enzyme
expressed in tumors. We suggest it is an interesting research target
to study functional interactions between Prx1 and hyaluronan
oligomers in production of inflammatory and anti-inflammatory
mediators through TLR4 in respect to tumor growth and metas-
tasis (Fig. 5 and 6).
7.2. Prx4 enhances tumor growth and metastasis. A re-
cent report shows that Prx4 is also important for human lung
cancer progression and metastasis.(144) This study used a micro-
array assay to compare gene expression patterns between normal
and tumor tissues. They first found that sulfiredoxin (Srx),
which catalyzes the reaction of hyperoxidized Prxs to the reduced
form, was highly expressed in tumor samples from patients with
aquamous cell carcinoma or adenocarcinoma. To explore the role
of Srx in lung tumors, they used human lung cancer cell lines
A549 and HEK293T as models. They found Srx knockdown
reduced anchorage-independence proliferation of the cells in soft
agar.(144) Then, Prx4 was identified as the most abundant Srx-
interacting protein in both A549 and HEK293T cells. Interest-
ingly, Prx4 knockdown recapitulated the phenotypic changes
induced by Srx knockdown in A549 cells. Inoculation of Srx
knocked-down cells into SCID immuno-deficient mice caused
reduced tumor growth and lung metastasis formation. In contrast,
inoculation of Srx plus Prx4 overexpressed cells caused an
opposite effect. They suggested that Srx and Prx4 play role in
intracellular phosphokinase signaling including AP-1-MMP9 and
MAPK cascades and that enhanced Srx and Prx4 expressions in
squamous cell carcinoma or adenocarcinoma contribute to tumor
progression and metastasis formation.(144)
It is noted, however, this study did not examine whether Srx
knockdown may also have caused functional defects of other
intracellular Prxs, and that Prx4 secreted from cells may act either
through yet unidentified cell receptor(s) or as an extracellular
antioxidant. It is also possible that Prx4 may protect tumor
cells from oxidative stress through facilitating degradation of
thromboxane A2 receptor, which is predominantly localized in the
endoplasmic reticulum.(145) Additionally, a possible cooperation of
Prx4 with Prx1 and Prx6 in modulating tumor progression should
be considered since A549 cells secrete Prx1(18) and their prolifera-
tion also depends on Prx6(146) as will be shown below.
7.3. Prx6 promotes tumor metastasis. Other groups showed
that Prx6 is also upregulated in some malignant human tissues
including lung(137,147) and breast.(148,149) Prx6 is the only mammalian
1-Cys peroxiredoxin and contributes in lung phospholipid
metabolism through GSH peroxidase and phospholipase A2 (PLA2)
activities.(150–152) Recent studies have shown Prx6 promotes
progression and metastasis of cancer cells.(146,153) Chang et al.(146)
showed that upregulation of Prx6 levels in human breast cancer
cell lines, MDA-MB-435 and MDA-MB-231, increased their
growth rates and adhesion to dishes in serum-free conditions.
Down-regulation of Prx6 expression caused opposite effects.
Parallel results to those in vitro assays were obtained in in vivo
inoculation of the Prx6-modified cancer cells, indicating Prx6
in tumors positively regulates tumor growth and pulmonary
metastasis in mice.(146) They observed that Prx6 expression levels
affects several gene expressions in both cultured cancer cells and
inoculated tumors.(146)
In contrast, Ho et al.(153) provided evidence that both peroxidase
and PLA2 activities of Prx6 are required for metastasis of human
lung cancer cells A549 and H460. They showed that enhanced
Prx6 expression in A549 cells significantly increased pulmonary
tumor nodule formation in the implanted nude mice compared to
control cells. This tumor enhancing effect was not observed when
the cells expressing Prx6 mutant lacking either peroxidase or
PLA2 activity was injected, respectively. Further analysis using
cultured cells and their implantation to hind legs, they concluded
that the endogenous Prx6 peroxidase activity was sufficient for
growth of the cells both in culture and in vivo leg inoculation.
Transfection of the peroxidase mutant C47S-Prx6 suppressed
the cell/tumor growth in a dominant-negative manner.(153) They
suggested that Prx6 peroxidase activity might contribute to
metastatic colony formation by facilitating cancer cell growth.
They further showed that arachidonic acid (AA) produced by the
PLA2 activity promotes cell invasion by stimulating the signaling
pathway involving p38 kinase, PI3K, Akt and urokinase-type
plasminogen activator.
Concerning tumor progression, we suggest Prx1-mediated
TLR4 signaling may link with Prx6 phospholipase activation
(Fig. 5). Previous studies have established that LPS treatment of
cells such as macrophages and synovial fibroblasts induce TLR4-
mediated MyD88- and TRIF-dependent ERK activation leading
cytosolic PLA2 activation and AA-COX-2-PGE2 synthesis.(154–156)
In a cell-free system, ERK and p38 phosphorylated Prx6 at Thr-
177, resulting in an 11-fold increase in PLA2 activity without
changing its GSH peroxidase activity.(157) Therefore, Prx1 instead
of LPS could also induce Prx6 phospholipase activation through
TLR4 signaling. Although there are several isoforms of PLA2
that can be activated through TLR4, Prx6 could play a major role
in tumor progression if the tumor expresses high Prx6 levels.
8. Prevention of Oncogenesis by Prx1
It is an interesting question whether or not host Prx1 is impor-
tant for suppressing spontaneous oncogenesis in vivo. The above
results that some inoculated tumor cells utilize their Prxs for their
progression in mice do not answer this question. Neumann et al.(158)
first proposed that Prx1 prevents spontaneous tumor generation by
reducing ROS levels and oxidative DNA damage. They showed
Prx1 deficient mice have a shortened lifespan owing to develop-
ment of severe hemolytic anaemia and several malignant cancers
over 9 months of age. It is important to note that lack of Prx1
causes various effects in cells since it directly binds with several
key molecules of the transformation such as PTEN and c-Myc
resulting modification of their activities.
Prx1 binds tumor suppressor PTEN to protect its lipid
phosphatase activity from inactivation under mild oxidative
stress (25 μM H2O2).(159) PTEN is a nonredundant phosphatase,
counteracting one of the most critical cancer-promoting pathways:
PI3K-Akt signaling pathway (see recent review by Zhang and
Yu(160)). It was shown that Akt is highly activated in Prx1 deficient
fibroblasts and mammary epithelial cells, under which condition
Ras or ErbB expression enhanced cell transformation.(159) Interest-
ingly, on the other hand PTEN deficiency in fibroblasts causes
60–80% decrease in Prx1, Prx2, Prx5, Prx6 and Cu/Zn-SOD
expression levels.(161) These results suggest Prx1 and PTEN
cooperate to maintain cellular antioxidant levels and to suppress
PI3K-Akt signaling.
Interaction of Prx1 with c-Myc to inhibit its transcriptional
activities is also important to protect cells from transformation.(23)
In Prx1 deficient fibroblasts and mice, some c-Myc functions, e.g.
suppression or enhancement of target genes, are altered. As the
results, the fibroblasts were transformed by a ras oncogene
alone.(23) Another study showed that activation of PI3K/Akt
signaling pathway by loss of PTEN function induces stabilization
of c-Myc protein in pancreatic cancer cells.(162) Overexpression of
c-Myc in focal prostate luminal epithelial cells and prostate-
specific deletion of PTEN induces high-grade prostatic intra-
epithelial neoplasia lesions.(163)
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tible to transformation at least due to reduced tumor suppressor
PTEN activity and also enhanced c-Myc activity. It is important to
note that Prx1 deficient embryonic fibroblasts grow more slowly
compared to wild type cells and do not spontaneously transform
during culture in vitro.(23,158) Additionally tumorigenesis in vivo
was not observed in other Prx1 single gene deficient mice like the
mouse strain used by Neumann et al.(158) We could not detect
tumor formation in our Prx1 deficient mice over one year breeding
under germ-free conditions.(164) This discrepancy may be due to
differences of mouse strain and/or breeding conditions. However,
there are good reasons to believe as discussed above that presence
of Prx1 in cells actually functions against tumorigenesis through
different manners in addition to its antioxidant activity.
9. Highlights and Future Perspectives
Recent evidence highlights novel functions of Prxs indepen-
dently of their peroxidase activity. One of the highlights is the
function of Prxs in extracellular space as modulators in inflam-
mation-related biological reactions as discussed above. Fig. 7
summarizes the multi-function of Prx1, the most characterized
Prx family protein. Prx1 is a unique protein that could interact with
many different types of proteins. Since inflammation reaction is
controlled by many different types of factors and cells, it is
important in the future studies to resolve fine roles of Prx1 and
other Prx family proteins in each reaction systems.
Functions of malarial and helminth parasite Prxs as immuno-
modulators(14,100,105) and their functional interaction with host
Prx1 and Prx2 will be an important subject of future research to
defend against parasite infections. Studies on the role of Prx1 and
other Prxs in tumor progression are also important to establish
novel strategies to suppress tumor growth and metastasis. Al-
though there are no reports to date, Prx1 may also interact with
TLR2 and other unknown cell surface receptors, and Prx2 may
also interact with TLR2 and TLR4. Their precise signaling
pathways through the receptors and their adaptors require further
characterization.
We would like to emphasize the importance of functional
interactions of Prx1 with low molecular weight hyaluronan,
LM-HA through TLRs (Fig. 3 and 6). Both Prx1 and LM-HA
interact with TLR4 but activate respectively different intracellular
signaling.(126,138) HA is the major matrix component and LM-HA
can be released upon tissue injury,(123) infection of nematode(165)
and tumor progression.(166,167) Functional interaction or signaling
cross talk between Prx1 and other stress proteins such as Hsp70
and Hsp60 may also be important. Hsp70 and Prx1 are abundant
intracellular molecules and they complement one another to make
cells resistant against various stresses such as heat shock and
oxidative stress. Hsp70 is also known to play dual roles in
apoptosis and innate immunity.(168,169) Both Hsp70 and Hsp60 are
secreted from cells and functions as immune modulators through
interaction with TLR2/4 and other cell surface receptors.(169–172)
Extracellular Hsp70 derived from stressed and damaged cells can
elicit a proinflammatory (Th1) immune response and enhance NK
cell activity like Prx1 and Prx2.(17)
Trx is also excreted from cells under oxidative stress and its
plasma levels are good markers for oxidative stress in variety of
disorders.(173) Trx in the circulation exhibits anti-apoptotic and
anti-inflammatory effects. Trx expression is enhanced in cancer
tissues like Prx1 and it stimulates growth of virus-transformed B
cells.(173) It will be an interesting in future studies to characterize
possible functional interactions of PrxI with Trx and Trx family
protein MIF in the extracellular space. Additionally, interaction of
extracellular Prxs with CyPA will be another future interesting
subject to study regulation of inflammatory reactions.
In summary, recent studies have opened a new era of Prx
research that is not restricted to its antioxidant activities. These
studies have revealed novel functions of Prxs in self-defense
against infection, tissue damages and tumors through the regula-
tion of inflammation. Further characterization of the roles of
Prx1/2 in TLR2/4-mediated signaling and on direct or functional
interaction with other inflammatory modulators are required to
unravel the physiological functions of Prxs in the complex
biological responses. Further studies using Prxs animal models
are required to clarify the in vivo roles of Prxs, which can not be
characterized in simple cell culture systems. These studies will
help to establish strategies for treatment of stress- and inflam-
mation-related wide variety of disorders.
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